ANTI CATHEPSIN B MARKET ANALYSIS

Market News

Global Anti-Cathepsin B Market: Key Developments

On April 13, 2023, Bio-Techne Corporation ,a company develops, manufactures and sells life science reagents, instruments and services for the research announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida. Bio-Techne's booth will feature its wide range of products, services and capabilities that enable cancer research and discoveries as well as cell and gene therapy development and workflow solutions including its industry-leading portfolio of reagents, immunoassays, proteomic analytical instruments, spatial biology solutions, and companion diagnostics capabilities.

On April 24, 2020, Elsevier B.V. announced that engineered human cathelicidin antimicrobial peptides inhibit ebola virus infection. Ebola VLPs were produced by co-expressing the EBOV matrix protein, VP40 (fused to β-lactamase), and the EBOV GP. Vero cells were pre-treated with AMPs (or cathepsin B inhibitor CA-074 methyl ester (at 50 μM as a positive control) for 1 h at 37°C and then infected with Ebola VLPs. At 4 h post-infection, a membrane-permeable β-lactamase substrate (CCF-2 AM) was added to the culture and incubated for 1 h at room temperature.